How to dose infliximab in rheumatoid arthritis: new data on a serious issue

被引：20

作者：

van Vollenhoven, Ronald F. ^{[1
]}

机构：

[1] Karolinska Inst, S-17176 Stockholm, Sweden

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2009年 / 68卷 / 08期

关键词：

NECROSIS-FACTOR-ALPHA; MONOCLONAL-ANTIBODY; CLINICAL-PRACTICE; DOUBLE-BLIND; PHASE-III; METHOTREXATE; PLACEBO; CA2;

D O I：

10.1136/ard.2009.111682

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1237 / 1239

页数：3

共 14 条

[1] Combination of infliximab and methotrexate therapy for early rheumatoid arthritis - A randomized, controlled trial [J].

Clair, EWS ;

van der Heijde, DMFM ;

Smolen, JS ;

Maini, RN ;

Bathon, JM ;

Emery, P ;

Keystone, E ;

Schiff, M ;

Kalden, JR ;

Wang, B ;

DeWoody, K ;

Weiss, R ;

Baker, D .

ARTHRITIS AND RHEUMATISM, 2004, 50 (11) :3432-3443

[2] The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis - Results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial [J].

Clair, EWS ;

Wagner, CL ;

Fasanmade, AA ;

Wang, B ;

Schaible, T ;

Kavanaugh, A ;

Keystone, EC .

ARTHRITIS AND RHEUMATISM, 2002, 46 (06) :1451-1459

[3] A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study [J].

Durez, P ;

Van den Bosch, F ;

Corluy, L ;

Veys, EM ;

De Clerck, L ;

Peretz, A ;

Malaise, M ;

Devogelaer, JP ;

Vastesaeger, N ;

Geldhof, A ;

Westhovens, R .

RHEUMATOLOGY, 2005, 44 (04) :465-468

[4] RANDOMIZED DOUBLE-BLIND COMPARISON OF CHIMERIC MONOCLONAL-ANTIBODY TO TUMOR-NECROSIS-FACTOR-ALPHA (CA2) VERSUS PLACEBO IN RHEUMATOID-ARTHRITIS [J].

ELLIOTT, MJ ;

MAINI, RN ;

FELDMANN, M ;

KALDEN, JR ;

ANTONI, C ;

SMOLEN, JS ;

LEEB, B ;

BREEDVELD, FC ;

MACFARLANE, JD ;

BIJL, H ;

WOODY, JN .

LANCET, 1994, 344 (8930) :1105-1110

[5]

ELLIOTT MJ, 1993, ARTHRITIS RHEUM, V36, P1681, DOI 10.1002/art.23362

[6] REPEATED THERAPY WITH MONOCLONAL-ANTIBODY TO TUMOR-NECROSIS-FACTOR-ALPHA (CA2) IN PATIENTS WITH RHEUMATOID-ARTHRITIS [J].

ELLIOTT, MJ ;

MAINI, RN ;

FELDMANN, M ;

LONGFOX, A ;

CHARLES, P ;

BIJL, H ;

WOODY, JN .

LANCET, 1994, 344 (8930) :1125-1127

[7] Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis [J].

Finckh, A. ;

Simard, J. F. ;

Gabay, C. ;

Guerne, P. -A. .

ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (06) :746-752

[8] Infliximab and methotrexate in the treatment of rheumatoid arthritis [J].

Lipsky, PE ;

van der Heijde, DMFM ;

St Clair, EW ;

Furst, DE ;

Breedveld, FC ;

Kalden, JR ;

Smolen, JS ;

Weisman, M ;

Emery, P ;

Feldmann, M ;

Harriman, GR ;

Maini, RN .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (22) :1594-1602

[9] Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate:: a randomised phase III trial [J].

Maini, R ;

St Clair, EW ;

Breedveld, F ;

Furst, D ;

Kalden, J ;

Weisman, M ;

Smolen, J ;

Emery, P ;

Harriman, G ;

Feldmann, M ;

Lipsky, P .

LANCET, 1999, 354 (9194) :1932-1939

[10] Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy [J].

Pavelka, K. ;

Jarosova, K. ;

Suchy, D. ;

Senolt, L. ;

Chroust, K. ;

Dusek, L. ;

Vencovsky, J. .

ANNALS OF THE RHEUMATIC DISEASES, 2009, 68 (08) :1285-1289

← 1 2 →